HIV/AIDS Topics IDWeek 2015: Post-Treatment Control of HIV Appears Rare, Biomarkers May Help Predict Rebound
- Details
- Category: Search for a Cure
- Published on Tuesday, 20 October 2015 00:00
- Written by Liz Highleyman
Only 4 individuals out of nearly 5000 people receiving care at U.S. military health facilities were found to exhibit immune control of HIV after starting antiretroviral therapy (ART), achieving viral suppression, and interrupting treatment, according to a presentation at IDWeek 2015 this month in San Diego. A recently published related study identified several biomarkers that may help predict who will be post-treatment controllers, a useful tool for HIV cure research.
IDWeek 2015: Many People with HIV Are Not Virally Suppressed on Antiretroviral Therapy
- Details
- Category: Cascade of Care
- Published on Sunday, 18 October 2015 00:00
- Written by Liz Highleyman
A third of people with HIV on antiretroviral therapy (ART) do not have sustained viral suppression and many are not receiving regimens recommended by the latest U.S. treatment guidelines, according to data from the Medical Monitoring Project presented at IDWeek 2015 last week in San Diego. However, this study included many people with long-term HIV infection who may not have been able to use preferred first-line regimens.
ICAAC 2015: No Transmission of Integrase Inhibitor-Resistant HIV Seen in California Patients
- Details
- Category: HIV Treatment
- Published on Sunday, 11 October 2015 00:00
- Written by Gus Cairns
Not one case of transmission of HIV that is resistant to any of the integrase inhibitor drugs has been seen among newly diagnosed patients in a database of resistance tests in California, according to a presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)last month in San Diego.
IDWeek 2015: Studies Continue to Support Tenofovir Alafenamide as it Nears Approval
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 14 October 2015 00:00
- Written by Liz Highleyman
A single-tablet regimen containing a new formulation of tenofovir maintained viral suppression when switching from other combinations and was associated with improved kidney function and bone health, according to studies presented at IDWeek 2105 last week in San Diego. Other research showed that the new formulation works better than the old one for black patients and for older people, and that it can be safely used with sofosbuvir/ledipasvir (Harvoni) for hepatitis C treatment.
IDWeek 2015: Affordable Care Act Coverage Improves Chances of HIV Viral Suppression
- Details
- Category: HIV Treatment
- Published on Thursday, 08 October 2015 00:00
- Written by HIVandHepatitis.com
Enrolling low-income and under-insured people with HIV in an Affordable Care Act (ACA) health plan improves their odds of having sustained antiretroviral treatment and undetectable viral load, according to a presentation at ID Week 2015 in San Diego. This study adds to the recent evidence confirming the benefits of providing healthcare coverage for people living with HIV.
IDWeek 2015: HIV Attachment Inhibitor BMS-663068 Matches Atazanavir in Phase 2b Study
- Details
- Category: Experimental HIV Drugs
- Published on Sunday, 11 October 2015 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's HIV attachment inhibitor BMS-663068 (fostemsavir), which prevents the virus from binding to T-cells, demonstrated good antiviral activity and was well-tolerated at 24 weeks, according to study results published recently in Lancet HIV. Findings from a subgroup analysis at 48 weeks, presented at IDWeek 2015 this week in San Diego, showed that response rates were similar regardless of demographics or baseline viral load or CD4 cell count.
IDWeek 2015 Features HIV and Hepatitis C Prevention, Treatment, and Cure Research
- Details
- Category: HIV Treatment
- Published on Wednesday, 07 October 2015 00:00
- Written by HIVandHepatitis.com
Immediate antiretroviral therapy is the big HIV news of the year and interferon-free therapy has transformed the treatment of hepatitis C despite its high cost, experts said during an overview of "What's Hot" in the field, presented at the IDWeek 2015 conference taking place this week in San Diego. Participants also heard a keynote talk by Ian Crozier, a doctor who survived Ebola virus disease.
More Articles...
- Coverage of 2015 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Coverage of IDWeek 2015
- High Standards of Care Associated with Reduced Mortality Risk for Veterans with HIV
- New WHO Guidelines Recommend HIV Treatment for All and PrEP for Those at Risk
- ICAAC 2015: New Antiretrovirals and HIV Treatment Strategies
Web Design and Development by